PAK4 and melanoma: PF-3758309, a potent ATP-competitive pyrrolopyrazole pan-PAK inhibitor, was reported to inhibit carcinomas, melanomas, and rhabdomyosarcomas by abrogating interactions of PAK1 and PAK4 with their corresponding substrates 14, 15, 33.